Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 29.5
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Lukas Biomedical Inc. engages in the development of immune cell medical technology for regenerative medicine and auxiliary treatment of cancer in Taiwan. It operates through four divisions: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. The company also wholesales and retails cosmetics; and rents housing equipment. Lukas Biomedical Inc. was founded in 2002 and...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell